- Conditions
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Interventions
- FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg, Placebo FDC, Placebo macitentan, Placebo tadalafil
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 26
- States / cities
- Fullerton, California • Los Angeles, California • Atlanta, Georgia + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 450
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Vascular Resistance, Hypertension
- Interventions
- Resveratrol, Placebo
- Dietary Supplement · Drug
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 50 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- IKT-001, Placebo
- Drug
- Lead sponsor
- Inhibikase Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 486 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Louisville, Kentucky • Boston, Massachusetts
- Conditions
- Focus Chronic Kidney Disease With Hypertension
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity, Sleep Apnea Syndrome
- Interventions
- Orlistat, Placebo
- Drug
- Lead sponsor
- Jack Yanovski
- NIH
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- APD811, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 9 more
- Conditions
- Hypertension Uncomplicated, Pre Hypertension
- Interventions
- High and low salt diets
- Diagnostic Test
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 30 participants
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Pre-Eclampsia
- Interventions
- Echocardiogrpahy and non-invasive monitoring
- Diagnostic Test
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Nitric Oxide
- Drug
- Lead sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Sleep Apnea, Obstructive, Hypertension, Pulmonary, Heart Failure
- Interventions
- AirSense™ 10 AutoSet, Standard Medical Therapy
- Device · Other
- Lead sponsor
- Albert Einstein Healthcare Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hypertension, Resistant to Conventional Therapy, Atrial Fibrillation
- Interventions
- Circumferential PV isolation, Circumferential PVI+renal denervation
- Procedure
- Lead sponsor
- Meshalkin Research Institute of Pathology of Circulation
- Network
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Overweight or Obesity, Prediabetes or Diabetes, Prehypertension (Elevated Blood Pressure) or Hypertension, Resistance Training
- Interventions
- Resistance Training
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 30 Years to 64 Years · Female only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Chronic Thromboembolic Pulmonary Hypertension, CTEPH
- Interventions
- Riociguat, Placebo, Pulmonary endarterectomy
- Drug · Procedure
- Lead sponsor
- International CTEPH Association
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Hypertension, Pulmonary, Lung Diseases, Interstitial
- Interventions
- TX000045
- Drug
- Lead sponsor
- Tectonic Operating Company, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- LTP001
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Mesa, Arizona
- Conditions
- Obstructive Sleep Apnea, Hypertension
- Interventions
- Inspiratory Muscle Strength Training
- Behavioral
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Beraprost Sodium Modified Release
- Drug
- Lead sponsor
- Lung Biotechnology PBC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 6
- States / cities
- Torrance, California • Naperville, Illinois • New York, New York + 3 more
- Conditions
- Hypertension in Pregnancy
- Interventions
- Impendence Cardiography
- Diagnostic Test
- Lead sponsor
- Marshall University
- Other
- Eligibility
- 15 Years to 45 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Huntington, West Virginia
- Conditions
- Sarcoidosis-associated Pulmonary Hypertension
- Interventions
- Selexipag, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Indianapolis, Indiana • New Orleans, Louisiana • New York, New York + 5 more
- Conditions
- Vitamin D Deficiency, Insulin Resistance, Type 2 Diabetes Mellitus, Cardiovascular Disease, Hypertension
- Interventions
- Vitamin D3, Placebo
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 25 Years to 80 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Obesity, Hyperlipidemia, Insulin Resistance, Hypertension
- Interventions
- Glutathione, N-Acetylcysteine, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Hypertension
- Interventions
- fenofibrate, Placebo
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Pulmonary Hypertension
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Arterial Hypertension, Atrial Fibrillation
- Interventions
- Circumferential PV isolation, PV isolation+renal denervation
- Procedure
- Lead sponsor
- Meshalkin Research Institute of Pathology of Circulation
- Network
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York